DOP2017000255A - Compuestos nucleósidos 5-sustituidos - Google Patents
Compuestos nucleósidos 5-sustituidosInfo
- Publication number
- DOP2017000255A DOP2017000255A DO2017000255A DO2017000255A DOP2017000255A DO P2017000255 A DOP2017000255 A DO P2017000255A DO 2017000255 A DO2017000255 A DO 2017000255A DO 2017000255 A DO2017000255 A DO 2017000255A DO P2017000255 A DOP2017000255 A DO P2017000255A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cancer
- compounds
- substituted nucleoside
- nucleoside compounds
- leukemia
- Prior art date
Links
- -1 NUCLEOSIDE COMPOUNDS Chemical class 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos nucleósidos 5'-sustituidos novedosos, composiciones farmacéuticas que comprenden los compuestos, y métodos de utilización de los compuestos para tratar el cáncer, más particularmente para el tratamiento del cáncer, en particular los glioblastomas, melanoma, sarcomas, cáncer gástrico, cáncer de páncreas , colangiocarcinoma, cáncer de vejiga, cáncer de mama, cáncer de pulmón de células no pequeñas, leucemias, incluyendo leucemia mieloide aguda y los linfomas .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382225 | 2015-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000255A true DOP2017000255A (es) | 2018-01-15 |
Family
ID=53177322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000255A DOP2017000255A (es) | 2015-05-04 | 2017-10-30 | Compuestos nucleósidos 5-sustituidos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9840532B2 (es) |
| EP (1) | EP3292128A1 (es) |
| JP (2) | JP6181889B1 (es) |
| KR (1) | KR20170132871A (es) |
| CN (1) | CN107580602A (es) |
| AR (1) | AR104326A1 (es) |
| AU (1) | AU2016258485A1 (es) |
| BR (1) | BR112017020336A2 (es) |
| CA (1) | CA2981097A1 (es) |
| CL (1) | CL2017002637A1 (es) |
| CO (1) | CO2017010727A2 (es) |
| CR (1) | CR20170443A (es) |
| DO (1) | DOP2017000255A (es) |
| EA (1) | EA201792169A1 (es) |
| EC (1) | ECSP17072987A (es) |
| HK (1) | HK1244007A1 (es) |
| IL (1) | IL254409A0 (es) |
| MA (1) | MA42036A (es) |
| MX (1) | MX2017014001A (es) |
| PE (1) | PE20180231A1 (es) |
| PH (1) | PH12017502002A1 (es) |
| SG (1) | SG11201708345XA (es) |
| TN (1) | TN2017000459A1 (es) |
| TW (1) | TWI615400B (es) |
| WO (1) | WO2016178870A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6584521B2 (ja) * | 2015-02-24 | 2019-10-02 | ファイザー・インク | 抗がん剤として有用な置換ヌクレオシド誘導体 |
| EP3574917A4 (en) * | 2017-01-27 | 2020-05-06 | University of Miyazaki | ANTI-DRUG MEDICINE, METHOD FOR SCREENING ON ANTI-DRUG MEDICINE, KIT FOR DETERMINING THE EFFECTIVENESS OF CANCER AND METHOD FOR DETERMINING THE EFFECTIVENESS OF CANCER |
| WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152548A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| PL3665179T3 (pl) * | 2017-08-09 | 2021-11-29 | Prelude Therapeutics, Incorporated | Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5) |
| WO2019084470A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| HUE059945T2 (hu) | 2017-12-13 | 2023-01-28 | Lupin Ltd | Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| BR112020018636A2 (pt) * | 2018-03-14 | 2020-12-29 | Prelude Therapeutics, Incorporated | Inibidores seletivos de proteína arginina metiltransferase 5 (prmt5) |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| AU2020223058A1 (en) * | 2019-02-13 | 2021-09-09 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (PRMT5) |
| WO2020206299A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| PL3980417T3 (pl) | 2019-06-10 | 2024-03-18 | Lupin Limited | Inhibitory prmt5 |
| WO2021055797A1 (en) * | 2019-09-18 | 2021-03-25 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| UA128683C2 (uk) | 2019-10-22 | 2024-09-25 | Люпін Лімітед | Фармацевтична комбінація на основі інгібіторів prmt5 |
| US20230066014A1 (en) | 2019-12-03 | 2023-03-02 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001027114A1 (en) * | 1999-08-27 | 2001-04-19 | Icn Pharmaceuticals, Inc. | PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| US9416154B2 (en) * | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP3406607A1 (en) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| US9611257B2 (en) | 2012-12-21 | 2017-04-04 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP6584521B2 (ja) | 2015-02-24 | 2019-10-02 | ファイザー・インク | 抗がん剤として有用な置換ヌクレオシド誘導体 |
-
2016
- 2016-04-20 AR ARP160101081A patent/AR104326A1/es unknown
- 2016-04-22 TW TW105112724A patent/TWI615400B/zh not_active IP Right Cessation
- 2016-04-27 MX MX2017014001A patent/MX2017014001A/es unknown
- 2016-04-27 TN TNP/2017/000459A patent/TN2017000459A1/en unknown
- 2016-04-27 HK HK18103599.9A patent/HK1244007A1/zh unknown
- 2016-04-27 MA MA042036A patent/MA42036A/fr unknown
- 2016-04-27 JP JP2016575652A patent/JP6181889B1/ja not_active Expired - Fee Related
- 2016-04-27 US US15/139,370 patent/US9840532B2/en not_active Expired - Fee Related
- 2016-04-27 SG SG11201708345XA patent/SG11201708345XA/en unknown
- 2016-04-27 BR BR112017020336-7A patent/BR112017020336A2/pt not_active Application Discontinuation
- 2016-04-27 CN CN201680025080.3A patent/CN107580602A/zh active Pending
- 2016-04-27 EP EP16720676.2A patent/EP3292128A1/en not_active Withdrawn
- 2016-04-27 PE PE2017002330A patent/PE20180231A1/es not_active Application Discontinuation
- 2016-04-27 AU AU2016258485A patent/AU2016258485A1/en not_active Abandoned
- 2016-04-27 CR CR20170443A patent/CR20170443A/es unknown
- 2016-04-27 KR KR1020177031713A patent/KR20170132871A/ko not_active Withdrawn
- 2016-04-27 WO PCT/US2016/029475 patent/WO2016178870A1/en not_active Ceased
- 2016-04-27 CA CA2981097A patent/CA2981097A1/en not_active Abandoned
- 2016-04-27 EA EA201792169A patent/EA201792169A1/ru unknown
-
2017
- 2017-02-15 JP JP2017025494A patent/JP2017125029A/ja active Pending
- 2017-09-11 IL IL254409A patent/IL254409A0/en unknown
- 2017-10-17 CL CL2017002637A patent/CL2017002637A1/es unknown
- 2017-10-20 CO CONC2017/0010727A patent/CO2017010727A2/es unknown
- 2017-10-30 DO DO2017000255A patent/DOP2017000255A/es unknown
- 2017-11-01 EC ECIEPI201772987A patent/ECSP17072987A/es unknown
- 2017-11-03 PH PH12017502002A patent/PH12017502002A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016258485A1 (en) | 2017-10-12 |
| US20160326208A1 (en) | 2016-11-10 |
| CL2017002637A1 (es) | 2018-04-20 |
| EP3292128A1 (en) | 2018-03-14 |
| EA201792169A1 (ru) | 2018-03-30 |
| MX2017014001A (es) | 2018-03-16 |
| CO2017010727A2 (es) | 2018-01-31 |
| JP6181889B1 (ja) | 2017-08-16 |
| JP2017525667A (ja) | 2017-09-07 |
| BR112017020336A2 (pt) | 2019-05-14 |
| CN107580602A (zh) | 2018-01-12 |
| CA2981097A1 (en) | 2016-11-10 |
| PH12017502002A1 (en) | 2018-03-26 |
| MA42036A (fr) | 2018-03-14 |
| WO2016178870A1 (en) | 2016-11-10 |
| TW201712022A (zh) | 2017-04-01 |
| PE20180231A1 (es) | 2018-01-31 |
| CR20170443A (es) | 2017-11-07 |
| HK1244007A1 (zh) | 2018-07-27 |
| SG11201708345XA (en) | 2017-11-29 |
| IL254409A0 (en) | 2017-11-30 |
| TN2017000459A1 (en) | 2019-04-12 |
| JP2017125029A (ja) | 2017-07-20 |
| ECSP17072987A (es) | 2018-02-28 |
| TWI615400B (zh) | 2018-02-21 |
| AR104326A1 (es) | 2017-07-12 |
| KR20170132871A (ko) | 2017-12-04 |
| US9840532B2 (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000255A (es) | Compuestos nucleósidos 5-sustituidos | |
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
| CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| CO2017000359A2 (es) | Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa | |
| JOP20200110A1 (ar) | متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات | |
| CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
| ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| NZ716392A (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| MX2017002824A (es) | Inhibidores demetilasa-1 especifica de lisina. | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| MX2017000179A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| DOP2017000053A (es) | Derivados de benzodiazepina citotóxicos | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| ECSP17020172A (es) | Inhibidores de histona desmetilasa | |
| CL2017001511A1 (es) | Derivados de piperidina como inhibidores de hdac1/2. | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX2018005305A (es) | Nuevos antiestrogenos heterociclicos. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |